title: Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy.
abstract: Since 1990, the primary criteria used for assessing response to therapy in high-grade gliomas were those developed by Macdonald and colleagues, which incorporated 2-dimensional area measurements of contrast-enhancing tumor regions, corticosteroid dosing, and clinical assessment to arrive at a designation of response, stable disease, or progression. Recent advances in imaging technology and targeted therapeutics, however, have exposed limitations of the Macdonald criteria and have highlighted the need for reevaluation of response assessment criteria. In 2010, the Response Assessment in Neuro-Oncology (RANO) Working Group published updated criteria to address this need and to standardize response assessment for high-grade gliomas. In 2009, prior to the publication of the RANO criteria, the randomized, placebo-controlled, multicenter, phase 3 AVAglio trial was designed and initiated to investigate the effectiveness of radiotherapy and temozolomide with or without bevacizumab in newly diagnosed glioblastoma. The AVAglio protocol enacted specific measures to adapt the Macdonald criteria to the frontline treatment setting and to antiangiogenic agent evaluation, including the incorporation of a T2/fluid-attenuated inversion recovery component, qualitative assessment of irregularly shaped contrast-enhancing lesions, and a decision tree for confirming or ruling out pseudoprogression. Moreover, the protocol outlines practical means by which these adapted response criteria can be implemented in the clinic. This article describes the evolution of radiographic response criteria for high-grade gliomas and highlights the similarities and differences between those implemented in the AVAglio study and those subsequently published by RANO.
authors.affiliation: Aix-Marseille University, AP-HM, Service de Neuro-Oncologie, CHU Timone, 264 Rue Saint Pierre, 13005, Marseille, France. olivier.chinot@ap-hm.fr
authors.forename: Olivier L
authors.initials: OL
authors.lastname: Chinot
authors.forename: David R
authors.initials: DR
authors.lastname: Macdonald
authors.forename: Lauren E
authors.initials: LE
authors.lastname: Abrey
authors.forename: Gudrun
authors.initials: G
authors.lastname: Zahlmann
authors.forename: Yannick
authors.initials: Y
authors.lastname: Kerloëguen
authors.forename: Timothy F
authors.initials: TF
authors.lastname: Cloughesy
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy*; D017326:Clinical Trials, Phase III as Topic; D018450:Disease Progression; D004311:Double-Blind Method; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D008279:Magnetic Resonance Imaging; D017063:Outcome Assessment, Health Care / Q000379:methods / Q000592:standards*; D016032:Randomized Controlled Trials as Topic
chemical_list: D020533:Angiogenesis Inhibitors